We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M Turnover 20%
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+5.7%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$379M
AUM Growth
+$697K
Cap. Flow
-$7.42M
Cap. Flow %
-1.96%
Top 10 Hldgs %
54.1%
Holding
70
New
14
Increased
14
Reduced
8
Closed
4
Avg Time Held
1.8 years
Top 10 Avg Time Held
1.1 years
Top 20 Avg Time Held
1.4 years

Top Buys

Rank Stock Value
1
SUPN icon
Supernus Pharmaceuticals
SUPN
+$6.21M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$5.89M
3
HRMY icon
Harmony Biosciences
HRMY
+$4.98M
4
INCY icon
Incyte
INCY
+$4.91M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$4.17M

Top Sells

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$18.3M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$14.3M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$8.11M
4
ILMN icon
Illumina
ILMN
+$6.26M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$5.95M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
GILD icon
1
Gilead Sciences
GILD
$195B
$27.7M 7.32%
402,784
+15,000
+4% +$1M
2016 Q4
18 quarters
ALNY icon
2
Alnylam Pharmaceuticals
ALNY
$31.3B
$25.2M 6.66%
149,000
+40,200
+37% +$5.89M
2017 Q3
15 quarters
SGEN
3
DELISTED
Seagen Inc. Common Stock
SGEN
$22.9M 6.04%
145,000
+12,000
+9% +$1.78M
2017 Q1
17 quarters
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$22.3M 5.88%
237,873
-155,127
-39% -$14.3M
2016 Q4
18 quarters
REGN icon
5
Regeneron Pharmaceuticals
REGN
$82B
$20.8M 5.49%
37,200
-6,600
-15% -$3.34M
2020 Q2
4 quarters
NBIX icon
6
Neurocrine Biosciences
NBIX
$13.9B
$20.1M 5.31%
207,000
– –
2017 Q3
15 quarters
PTCT icon
7
PTC Therapeutics
PTCT
$5.09B
$18.9M 5%
449,000
+41,000
+10% +$1.76M
2019 Q1
9 quarters
BHVN icon
8
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$17.1M 4.52%
176,400
– –
2020 Q2
4 quarters
BIIB icon
9
Biogen
BIIB
$34.8B
$16.8M 4.43%
48,500
– –
2018 Q4
10 quarters
VRTX icon
10
Vertex Pharmaceuticals
VRTX
$129B
$13.1M 3.45%
64,822
-20,500
-24% -$4.29M
2016 Q4
18 quarters
AMGN icon
11
Amgen
AMGN
$235B
$12.4M 3.28%
51,000
+8,000
+19% +$1.97M
2018 Q4
10 quarters
INCY icon
12
Incyte
INCY
$23B
$11.5M 3.04%
136,860
+58,860
+75% +$4.91M
2016 Q4
18 quarters
QURE icon
13
uniQure
QURE
$1.56B
$9.71M 2.56%
315,500
+33,466
+12% +$1.12M
2019 Q2
8 quarters
TPTX
14
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$9.48M 2.5%
121,541
+40,000
+49% +$2.96M
2019 Q4
6 quarters
UTHR icon
15
United Therapeutics
UTHR
$23.2B
$7.77M 2.05%
43,300
+16,700
+63% +$3.18M
2021 Q1
1 quarter
XLRN
16
DELISTED
Acceleron Pharma
XLRN
$7.59M 2%
60,500
– –
2019 Q1
9 quarters
IONS icon
17
Ionis Pharmaceuticals
IONS
$7.33B
$7.25M 1.91%
181,781
-152,000
-46% -$5.95M
2017 Q1
17 quarters
PTGX icon
18
Protagonist Therapeutics
PTGX
$8.84B
$6.81M 1.8%
152,000
– –
2020 Q3
3 quarters
KALV icon
19
DELISTED
KalVista Pharmaceuticals
KALV
$6.79M 1.79%
283,233
+68,700
+32% +$1.8M
2016 Q4
18 quarters
SUPN icon
20
Supernus Pharmaceuticals
SUPN
$2.3B
$6.23M 1.65%
+202,436
New +$6.21M
2021 Q2
0 quarters
RARE icon
21
Ultragenyx Pharmaceutical
RARE
$1.5B
$5.73M 1.51%
60,100
+40,000
+199% +$4.17M
2021 Q1
1 quarter
HRMY icon
22
Harmony Biosciences
HRMY
$2.23B
$4.69M 1.24%
+166,000
New +$4.98M
2021 Q2
0 quarters
BMRN icon
23
BioMarin Pharmaceuticals
BMRN
$10.8B
$4.6M 1.22%
55,156
– –
2016 Q4
18 quarters
CCXI icon
24
DELISTED
ChemoCentryx, Inc.
CCXI
$4.04M 1.07%
58,100
-230,500
-80% -$5.68M
2020 Q1
5 quarters
AUPH icon
25
Aurinia Pharmaceuticals
AUPH
$2.23B
$3.87M 1.02%
298,500
– –
2020 Q3
3 quarters
1
2 3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q2 2021 Portfolio in Review

As of Q2 2021, International Biotechnology Trust held 70 positions worth $379M, up 0.18% from $378M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

International Biotechnology Trust's Q2 2021 filing shows 14 new, 14 increased, 8 reduced and 4 closed positions. Its largest new stake was Supernus Pharmaceuticals: 202,436 shares worth $6.23M. The largest sale was Exelixis, an estimated $18.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • International Biotechnology Trust's largest Q2 2021 buy was Supernus Pharmaceuticals: 202,436 shares worth $6.23M.
  • International Biotechnology Trust added most to Alnylam Pharmaceuticals in Q2 2021, an estimated $5.89M increase.
  • International Biotechnology Trust's biggest Q2 2021 reduction was Exelixis, cutting an estimated $18.3M.
  • International Biotechnology Trust fully exited Illumina in Q2 2021, selling an estimated $6.26M.
  • International Biotechnology Trust's ten largest holdings make up 54% of its $379M portfolio in Q2 2021.
  • International Biotechnology Trust opened 14 new positions and closed 4 in Q2 2021.
  • International Biotechnology Trust's portfolio value rose 0.18% quarter-over-quarter to $379M.

Based on International Biotechnology Trust's 13F filing for Q2 2021, filed 11 Aug 2021.